Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nichi-Iko Pharmaceutical Co., Ltd.

http://www.nichiiko.co.jp/english

Latest From Nichi-Iko Pharmaceutical Co., Ltd.

Lupin CEO On ProAir Generic Site Transfer, Digital Plans

Lupin CEO Vinita Gupta shares plans to shift manufacture of albuterol and some other products to its US facilities, with a rollout of a generic to Teva’s ProAir expected soon. Enthused by Lupin’s first biosimilar introduction In Europe with etanercept and looking to up the company’s digital game, the executive says Amazon’s entry into India’s e-pharmacy space is not a near-term worry

India Commercial

Lupin Cuts Forecast Despite Etanercept Launch

Despite plans to launch a biosimilar to Enbrel in August and a generic to ProAir in September, Lupin cut its FY21 EBITDA forecast to 17% from 19-20%, as first-quarter revenues were hit by COVID-19 and a recall of metformin in the US. Meanwhile, it sees the US “Buy American” order for some essential medicines as a near-term opportunity.

Sales & Earnings India

Despite Imminent Etanercept Launch, Lupin Cuts FY21 Forecast

Despite plans to launch a biosimilar to Enbrel in August and a generic to ProAir in September, Lupin cut its FY21 EBITDA forecast to 17% from 19-20%, as first-quarter revenues were hit by COVID-19 and a recall of metformin in the US. Meanwhile, it sees the US “Buy American” order for some essential medicines as a near-term opportunity

Commercial Sales & Earnings

Coronavirus Update: How Should Remdesivir Be Priced? ICER Are In Two Minds

Independent drug cost watchdog updates its twin pricing estimates for Gilead's drug - but dexamethasone could tip the balance again.

Companies Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Elmed Eisai Co., Ltd
    • Nichi-Iko Medical Practice Institution Co., Ltd.
    • Yakuhan Pharmaceutical Co., Ltd.
    • Nichi-Iko Pharma Tech Co., Ltd.
    • Omega Laboratories Limited
    • Sagent Pharmaceuticals Inc.
    • Nihon Iyakuhin Kogyo Co., Ltd.
UsernamePublicRestriction

Register